Hello folks, In case you have not heard yet, we want to share some recent good news for multiple myeloma patients and their caregivers. Two new drugs have been approved for multiple myeloma in just the past couple of weeks — Talvey (also known as talquetamab-tgvs) and Elrexfio (also known as elranatamab-bcmm). Both of these drugs are immunotherapy drugs called Bi-specific T-Cell Engagers (BiTEs). One part of the drug binds to a protein on the patient’s T-cells, which are an important part of the immune system. Another part of the drug attaches to a protein on myeloma cells. Then, when the T-cells and myeloma cells are close together, the T-cells can destroy the myeloma cells. For more information about Talvey: https://www.jnj.com/u-s-fda-approves-talvey-talquetamab-tgvs-a-first-in-class-bispecific-therapy-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma For more information on Elrexfio: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elrexfiotm-receives-us-fda-accelerated-approval Cheers!